NON-MUSCLE INVASIVE BLADDER CANCER

This study compares several FDA-approved drugs for non-muscle invasive bladder cancer that has not responded to standard BCG therapy. About 125 adults will receive either a newer gene therapy (nadofaragene firadenovec) or one of several standard treatments. The goal is to see whi…

This study compares a new drug delivery system, TAR-210, to standard chemotherapy for people with a certain type of bladder cancer that hasn't spread into the muscle. The TAR-210 system delivers erdafitinib directly into the bladder, targeting tumors with specific genetic changes…

This program provides access to an experimental treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer that has not responded to standard therapy. It is for patients with non-muscle invasive bladder cancer that includes carcinoma in situ. The goa…

This early-stage study tests a drug called Sacituzumab Tirumotecan (Sac-TMT) given directly into the bladder for people with intermediate-risk non-muscle invasive bladder cancer that has come back. The main goals are to check the drug's safety and find the highest dose people can…

This study compares a new approach using a chemotherapy drug (MMC) directly into the bladder to standard surgery for people with recurrent low-grade bladder cancer. About 272 adults with small tumors will be randomly assigned to either the drug treatment or surgery followed by st…

This early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for people with a type of bladder cancer that hasn't spread into the muscle layer. The drug is injected directly into the tumor, sometimes with a laser, to see if it's safe and possible to do. Abo…

This early-stage study is testing a new drug called 2141-V11 for safety in 55 people with a type of bladder cancer that didn't get better with standard treatment. The drug is given directly into the bladder through a tube. The goal is to find the safest dose and see how the body …

This early-stage trial tests a new drug called PPM, which are tiny particles that carry chemotherapy directly to bladder cancer cells. The study is for people with non-muscle-invasive bladder cancer that did not get better with the standard BCG treatment. Up to 29 participants wi…

This study tests two drugs, durvalumab and monalizumab, given together monthly for up to a year in people with a type of bladder cancer that hasn't been cured by standard therapy. The goal is to see if the combination can make the cancer disappear completely. About 60 adults with…

This early-stage trial tests a new drug called STM-416 that is given directly into the bladder during surgery to remove recurrent high-grade papillary bladder tumors. The study involves 75 adults with a history of this cancer who are at high risk for recurrence. The main goals ar…

This study tests whether adding the drug bicalutamide to standard BCG therapy can lower the chance of bladder cancer returning. About 160 men with non-muscle invasive bladder cancer will be randomly assigned to receive either BCG alone or BCG plus bicalutamide. The goal is to see…

This study tests a new drug, TARA-002, given directly into the bladder for people with a high-grade type of bladder cancer that hasn't spread into the muscle. The goal is to see if it can make the cancer disappear. About 131 adults will take part, including those who have never h…

This study tests a new drug called cretostimogene in people with a type of bladder cancer that did not get better with standard therapy (BCG). The goal is to see if the drug can make tumors disappear and keep them from coming back. About 16 adults with high-risk, non-muscle invas…

This study compares a newer, single surgery using special dye and light (PDD-TURBT) against the standard approach of two surgeries for early-stage bladder cancer. About 112 adults with non-muscle invasive bladder cancer will be randomly assigned to either the new single-surgery m…

This early-stage study tests a new drug, PF-08052667, for adults with a type of bladder cancer that hasn't spread into the bladder muscle but is likely to return. The drug is given alone or with standard treatments like BCG and/or sasanlimab. The goal is to check safety and find …

This study gathers videos and data from 500 adults undergoing blue light cystoscopy for bladder cancer. The goal is to train an artificial intelligence (AI) system to help doctors find suspicious spots in real time. Participants receive standard care, and their anonymous recordin…

This study compares two types of scans—CT and MRI—to see which one is better at determining if bladder cancer has spread into the muscle layer. About 150 adults with newly diagnosed bladder cancer will receive both scans before surgery, and the results will be checked against tis…

This study tests whether a bladder rinse called Hydeal Cyst® can reduce urinary symptoms in people with non-muscle invasive bladder cancer who are receiving standard chemotherapy or immunotherapy. About 200 adults will receive either standard treatment alone or standard treatment…

This study is creating a large registry of up to 8,000 people with non-muscle-invasive bladder cancer in France. Doctors will record how patients are treated and followed over time, including results from urine tests and bladder exams. The goal is to find better ways to detect ca…

This study explores whether the standard BCG treatment for non-muscle invasive bladder cancer causes mood changes. About 42 participants will provide blood and urine samples and complete mood questionnaires and daily diaries. The goal is to understand the link between the body's …

This study looks at how tiny organisms (microbiome) and immune system markers relate to different bladder and urinary tract conditions. Researchers will collect urine, tissue, and stool samples from 800 adults with issues like UTIs, pelvic pain, overactive bladder, or bladder can…

This study looks at whether urine testing can safely replace some of the invasive cystoscopy procedures used to monitor non-muscle invasive bladder cancer. Researchers will compare symptoms, discomfort, anxiety, and cancer outcomes between patients who get standard care and those…